Mandate

Vinge advises Bregal Unternehmerkapital on its acquisition of Iptor

January 07, 2020 M&A

Vinge has advised Bregal Unternehmerkapital on its acquisition of Iptor from Marlin Equity Partners.

Iptor is a global leader in enterprise resource planning, supply chain management, planning and logistics software and services. Serving 1,250 customers in more than 40 countries, Iptor provides fully integrated enterprise solutions, with highly adaptable and robust software backed by world-class support from distribution and supply chain experts.

Vinge’s team consisted of Christina Kokko, Ulrich Ziche, Carl Sander, Martin Cronsioe, Fredric Reissmüller, Viktor Lennartsson and Karl Klackenberg (M&A), Albert Wållgren and Ludvig Wettergren (Banking and Finance), Jolene Reimerson, Jasmin Draszka, Mika Jordan, Fredrika Hjelmberg, Lisa Hörnqvist and Sofia Landolsi (Commercial Agreements), Jakob Kraus (IP), Lisa Ullman and Sophia Holm (Employment), Karolina Cohrs (Real Estate) and VDR assistants Viktoria Owetz and Christoffer Widström.

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025